Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06588192
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-05
Brief Title:
Renal Survival in Patients with Lupus Nephritis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Renal Survival in Patients with Lupus Nephritis in Assiut University Hospital a Single-center Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Systemic lupus erythematous is a chronic multifactorial autoimmune disease that affects many organs including kidney Lupus nephritis is a common manifestation characterized by heterogeneous clinical and histopathological finding and often associate with poor progression and despite potent anti-inflammatory and immunosuppressive therapies still end in CKD or ESRD for too many patient lupus nephritis is an immune complex GN that develop as a frequent complication of SLE The pathogenesis of lupus nephritis involve a variety of pathogenic mechanisms intra renal pathomechanisn of SLE related nephritis immune complex formation and classical complement pathway activation Lupus nephritis doesn39t develop in the absence of antinuclear antibodies Circulating polyclonal autoantibodies bind to intrarenal nucleosomes and other autoantigen which lead to local complement activation cell injury and subsequent cytokine and chemokine secretion The current management of lupus nephritis remain based on steroids cyclophosphamide azathioprine mycophenolate mefetile which are all unselective immunosuppressive drugs these drugs have proven to be efficient in reducing lupus nephritis disease activity but the long term outcomes of lupus nephritis have not further improved during the last 30 years Identification of renal survival is mandatory for certain purposes ie evaluation of efficacy of different treatment strategies among our patients and factors associated with the survival data as compared with other specialized centers
Detailed Description:
Systemic lupus erythematous is a chronic multifactorial autoimmune disease that affects many organs including kidney Lupus nephritis is a common manifestation characterized by heterogeneous clinical and histopathological finding and often associate with poor progression and despite potent anti-inflammatory and immunosuppressive therapies still end in CKD or ESRD for too many patient lupus nephritis is an immune complex GN that develop as a frequent complication of SLE The pathogenesis of lupus nephritis involve a variety of pathogenic mechanisms intra renal pathomechanisn of SLE related nephritis immune complex formation and classical complement pathway activation Lupus nephritis doesn39t develop in the absence of antinuclear antibodies Circulating polyclonal autoantibodies bind to intrarenal nucleosomes and other autoantigen which lead to local complement activation cell injury and subsequent cytokine and chemokine secretion The current management of lupus nephritis remain based on steroids cyclophosphamide azathioprine mycophenolate mefetile which are all unselective immunosuppressive drugs these drugs have proven to be efficient in reducing lupus nephritis disease activity but the long term outcomes of lupus nephritis have not further improved during the last 30 years Identification of renal survival is mandatory for certain purposes ie evaluation of efficacy of different treatment strategies among our patients and factors associated with the survival data as compared with other specialized centers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None